Supported by an unrestricted scientific grant from Centocor. Fabian Schnitzler received a research grant by ECCO (European Crohn's and Colitis Organisation).
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy†
Article first published online: 6 JAN 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 17, Issue 9, pages 1846–1854, September 2011
How to Cite
Schnitzler, F., Fidder, H., Ferrante, M., Ballet, V., Noman, M., Van Assche, G., Spitz, B., Hoffman, I., Van Steen, K., Vermeire, S. and Rutgeerts, P. (2011), Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis, 17: 1846–1854. doi: 10.1002/ibd.21583
- Issue published online: 9 AUG 2011
- Article first published online: 6 JAN 2011
- Manuscript Accepted: 22 OCT 2010
- Manuscript Received: 16 OCT 2010
- 2Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006; 101: 1274–1282., , , et al.Direct Link:
- 8Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998; 93: 2426–2430., , , et al.Direct Link:
- 14Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology. 2009; 136: A–27., , , et al.
- 16Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004; 99: 2385–2392., , , et al.Direct Link:
- 20Safety of Inliximab in Crohn's disease: data from the 5000 patient TREAT registry. Gastroenterology. 2004; 126: A54., , , et al.